CRNX vs RYTM
CRNX: A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across multiple endocrine diseases. RYTM: Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related neuroendocrine diseases.
Side-by-side fundamentals
| Metric | CRNX | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $83.63 | $105.74 | |
| Market cap as of 2026-07-31 | $8.9B | $7.2B | |
| PEG as of 2026-07-31 | -0.47 | -2.96 | RYTM lower |
| Net margin as of 2026-07-31 | -2747.2% | -93.3% | RYTM higher |
| Gross margin as of 2026-07-31 | +86.0% | +89.4% | RYTM higher |
| Operating margin as of 2026-07-31 | -3020.3% | -90.9% | RYTM higher |
| ROE as of 2026-07-31 | -44.0% | -86.5% | CRNX higher |
| ROA as of 2026-07-31 | -39.6% | -45.0% | CRNX higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.46 | CRNX lower |
| Revenue growth (YoY) as of 2026-07-31 | +2277.5% | +58.7% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +100.2% | |
| Beta as of 2026-07-31 | 1.10 | 0.87 | |
| 1-year return as of 2026-07-30 close | +186.1% | +24.9% | CRNX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.